Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free CRMD Stock Alerts

CorMedix (CRMD) Financials

CorMedix logo
$7.72 -0.07 (-0.90%)
Closing price 04:00 PM Eastern
Extended Trading
$7.75 +0.03 (+0.39%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for CorMedix

Annual Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -18 -25 -33 -27 -44 -22 -28 -30 -46 -18 163
Consolidated Net Income / (Loss)		 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18 163
Net Income / (Loss) Continuing Operations		 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18 163
Total Pre-Tax Income 		-18 -25 -33 -27 -21 -27 -29 -30 -46 -19 150
Total Operating Income		 -17 -25 -33 -27 -21 -27 -29 -31 -49 -22 150
Total Gross Profit		 -0.11 -0.14 0.21 0.03 -0.09 0.03 0.04 0.06 0.00 40 276
Total Revenue		 0.21 0.22 0.33 0.43 0.28 0.24 0.19 0.07 0.00 43 298
Operating Revenue		 0.21 0.22 0.33 0.43 0.28 0.24 0.19 0.07 - 43 298
Total Cost of Revenue		 -0.32 0.37 0.11 0.40 0.37 0.20 0.15 0.00 0.00 3.03 22
Operating Cost of Revenue		 0.32 0.37 0.11 0.40 0.37 0.20 0.15 0.00 - 3.03 22
Total Operating Expenses		 17 25 33 27 21 27 29 31 49 63 126
Selling, General & Admin Expense		 10 8.88 8.65 8.07 9.87 14 16 20 18 30 68
Marketing Expense		 - - - - - - - - 18 29 38
Research & Development Expense		 6.28 16 24 19 11 13 13 11 13 3.94 19
Total Other Income / (Expense), net		 -1.53 0.12 -0.17 0.03 -0.49 0.11 -0.02 0.34 2.62 3.03 -0.13
Interest Expense		 0.00 0.00 0.01 0.00 0.79 0.03 0.02 0.03 0.03 0.04 2.78
Interest & Investment Income		 0.06 0.13 0.11 0.03 0.32 0.12 0.01 0.33 2.68 2.58 3.85
Other Income / (Expense), net		 -1.59 -0.01 -0.28 -0.00 -0.02 0.02 -0.02 0.04 -0.03 0.49 -1.19
Income Tax Expense		 - - - 0.00 -5.06 -5.17 -1.25 -0.59 0.00 -1.40 -13
Basic Earnings per Share		 ($0.58) ($0.65) ($0.60) ($1.51) ($1.80) ($0.77) ($0.75) ($0.74) ($0.91) ($0.30) $2.25
Weighted Average Basic Shares Outstanding		 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 40.27M 50.90M 58.87M 72.03M
Diluted Earnings per Share		 ($0.58) ($0.65) ($0.60) ($1.51) ($1.80) ($0.77) - - ($0.91) ($0.30) $2.04
Weighted Average Diluted Shares Outstanding		 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 44.50M 50.90M 58.87M 80.31M
Weighted Average Basic & Diluted Shares Outstanding		 31.34M 37.97M 55.14M 17.82M 24.15M 28.56M 37.67M 44.50M 54.98M 65.18M 79.05M

Quarterly Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -15 -14 -14 -2.78 13 21 20 109 14 39 26
Consolidated Net Income / (Loss)		 -15 -14 -14 -2.78 13 21 20 109 14 39 26
Net Income / (Loss) Continuing Operations		 -15 -14 -14 -2.78 13 21 20 109 14 39 26
Total Pre-Tax Income 		-15 -16 -14 -2.78 13 21 20 53 56 56 39
Total Operating Income		 -16 -17 -15 -3.29 13 20 20 51 59 64 43
Total Gross Profit		 - -0.82 0.30 11 30 37 38 93 107 105 77
Total Revenue		 - 0.00 0.81 11 31 39 40 101 118 127 102
Operating Revenue		 - 0.00 0.81 11 31 39 40 101 118 127 102
Total Cost of Revenue		 - 0.82 0.51 0.63 1.18 1.60 1.86 7.57 11 22 25
Operating Cost of Revenue		 - 0.82 0.51 0.63 1.18 1.60 1.86 7.57 11 22 25
Total Operating Expenses		 16 16 16 14 17 17 18 42 48 41 34
Selling, General & Admin Expense		 2.58 8.71 7.56 6.58 0.77 9.69 9.50 25 24 22 15
Marketing Expense		 - 6.34 7.39 6.75 - 4.47 6.38 11 16 13 12
Research & Development Expense		 2.29 0.84 0.65 0.73 1.73 3.19 2.44 5.10 8.60 7.21 6.68
Total Other Income / (Expense), net		 0.91 0.84 1.15 0.51 1.03 0.52 0.81 1.23 -2.68 -8.01 -4.18
Interest & Investment Income		 0.92 0.86 0.66 0.55 0.51 - 0.00 1.56 0.89 - 2.55
Other Income / (Expense), net		 0.00 -0.00 0.50 -0.03 0.53 0.52 0.81 0.62 -1.75 -8.01 -6.72
Income Tax Expense		 - -1.39 0.00 0.00 - 0.00 0.52 -56 42 17 13
Basic Earnings per Share		 ($0.25) ($0.25) ($0.25) ($0.05) $0.25 $0.32 $0.29 $1.42 $0.22 $0.48 $0.33
Weighted Average Basic Shares Outstanding		 50.90M 57.50M 57.62M 58.83M 58.87M 65.24M 67.93M 75.93M 72.03M 79.51M 78.44M
Diluted Earnings per Share		 - ($0.25) ($0.25) ($0.05) - $0.30 $0.28 $1.26 $0.20 $0.43 $0.29
Weighted Average Diluted Shares Outstanding		 50.90M 57.50M 57.62M 58.83M 58.87M 68.98M 71.92M 86.21M 80.31M 92.99M 92.48M
Weighted Average Basic & Diluted Shares Outstanding		 54.98M 54.96M 55.86M 60.68M 0.00 67.82M 74.65M 78.79M 79.05M 78.45M 77.94M

Annual Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 7.48 -3.75 2.32 7.24 -1.27 26 11 -10 0.45 -3.07 105
Net Cash From Operating Activities		 -13 -22 -29 -24 -15 -22 -21 -24 -38 -51 175
Net Cash From Continuing Operating Activities		 -13 -22 -29 -24 -15 -22 -21 -24 -38 -51 175
Net Income / (Loss) Continuing Operations		 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18 163
Consolidated Net Income / (Loss)		 -18 -25 -33 -27 -16 -22 -28 -30 -46 -18 163
Depreciation Expense		 0.02 0.03 0.04 0.07 0.07 0.13 0.06 0.08 0.07 0.15 0.68
Amortization Expense		 - - 0.00 0.00 0.31 0.03 0.12 0.12 0.13 0.30 15
Non-Cash Adjustments To Reconcile Net Income		 5.64 2.59 1.51 1.11 2.54 0.66 5.05 4.07 5.49 6.27 8.63
Changes in Operating Assets and Liabilities, net		 0.01 -0.23 2.88 1.94 -1.54 -0.76 1.84 1.07 2.23 -39 -12
Net Cash From Investing Activities		 -24 11 10 1.56 -12 7.43 -9.13 -3.71 -17 21 -308
Net Cash From Continuing Investing Activities		 -24 11 10 1.56 -12 7.43 -9.13 -3.71 -17 21 -308
Purchase of Property, Plant & Equipment		 -0.02 -0.06 -0.15 -0.05 -0.04 -0.11 -1.43 -0.22 -0.33 -0.12 -2.26
Acquisitions		 - - - - - - - - - 0.00 -309
Purchase of Investments		 -24 0.00 -13 0.00 -14 -8.55 - -31 -77 -27 -53
Sale and/or Maturity of Investments		 - 11 24 1.60 2.12 16 -7.71 28 60 48 55
Net Cash From Financing Activities		 44 7.09 21 29 26 40 42 18 56 26 238
Net Cash From Continuing Financing Activities		 44 7.09 21 30 26 40 42 18 56 26 238
Repayment of Debt		 0.00 - - 0.00 - - - - - 0.00 -0.19
Repurchase of Common Equity		 - - - - -0.23 - - - - 0.00 -5.73
Issuance of Debt		 - - 0.00 7.50 2.00 - - - - 0.00 150
Issuance of Common Equity		 28 6.23 19 22 15 40 41 18 56 19 90
Other Financing Activities, net		 15 0.86 0.01 0.04 8.80 0.41 0.30 0.13 0.09 7.44 4.21
Effect of Exchange Rate Changes		 -0.02 0.00 0.02 -0.01 -0.00 0.01 -0.01 -0.01 0.00 -0.00 0.00
Cash Interest Paid		 0.00 0.00 0.01 0.00 0.01 0.03 0.02 0.03 0.03 0.04 0.02

Quarterly Cash Flow Statements for CorMedix

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -9.68 -8.46 -6.71 6.75 5.36 26 93 -110 96 33 70
Net Cash From Operating Activities		 -11 -17 -14 -14 -5.61 20 30 31 94 42 86
Net Cash From Continuing Operating Activities		 -11 -17 -14 -14 -5.75 20 30 31 95 43 78
Net Income / (Loss) Continuing Operations		 -15 -14 -14 -2.78 13 21 20 109 14 39 26
Consolidated Net Income / (Loss)		 -15 -14 -14 -2.78 13 21 20 109 14 39 26
Depreciation Expense		 0.02 0.02 0.02 0.03 0.08 0.16 0.11 0.16 0.29 11 11
Non-Cash Adjustments To Reconcile Net Income		 1.22 2.44 1.26 1.23 1.19 3.55 2.68 1.20 1.26 8.85 -6.03
Changes in Operating Assets and Liabilities, net		 2.74 -5.35 -1.27 -12 -21 -4.62 7.29 -83 68 -15 47
Net Cash From Investing Activities		 0.60 8.94 6.27 6.32 -0.30 -0.20 -20 -291 3.30 2.97 -0.56
Net Cash From Continuing Investing Activities		 0.60 8.94 6.27 6.32 -0.30 -0.20 -20 -291 3.30 2.97 -0.56
Purchase of Property, Plant & Equipment		 -0.30 -0.06 -0.03 -0.01 -0.01 -0.01 -0.02 -0.51 -1.72 -0.73 -0.56
Net Cash From Financing Activities		 0.47 -0.10 1.06 14 11 6.09 83 151 -1.41 -12 -7.07
Net Cash From Continuing Financing Activities		 0.47 -0.10 1.06 14 11 6.09 83 151 -1.41 -12 -7.07
Repayment of Debt		 - - - - - 0.00 - - -0.14 -0.14 -0.18
Repurchase of Common Equity		 - - - - - 0.00 - - -5.45 -11 -6.39
Other Financing Activities, net		 0.03 -0.10 0.05 1.71 5.78 -0.67 0.88 0.86 3.15 -0.87 -0.50

Annual Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 37 22 13 19 29 49 69 62 82 119 826
Total Current Assets		 37 22 13 19 29 48 66 60 79 115 367
Cash & Equivalents		 12 8.06 10 18 16 42 53 43 44 41 145
Short-Term Investments		 24 12 1.60 0.00 12 4.44 12 16 32 11 3.69
Accounts Receivable		 0.32 0.01 0.06 0.01 0.00 0.00 0.05 - 0.00 52 171
Inventories, net		 0.38 0.17 0.59 0.43 0.34 0.14 0.00 0.00 2.11 7.60 30
Prepaid Expenses		 0.81 1.32 0.45 0.43 0.48 1.47 0.82 0.63 1.24 3.63 18
Plant, Property, & Equipment, net		 0.04 0.07 0.19 0.16 0.12 0.11 1.47 1.61 1.87 1.83 5.96
Total Noncurrent Assets		 0.01 0.01 0.00 0.00 0.00 1.01 1.00 0.88 0.74 2.44 453
Long-Term Investments		 - - - - - - 0.10 0.10 0.10 0.11 28
Goodwill		 - - - - - - - - - 0.00 30
Intangible Assets		 - - - - - - - - 0.00 1.84 379
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - - 0.00 16
Total Liabilities & Shareholders' Equity		 37 22 13 19 29 49 69 62 82 119 826
Total Liabilities		 3.09 4.09 6.26 14 5.83 5.09 6.15 6.98 12 34 421
Total Current Liabilities		 3.06 4.09 6.26 7.77 5.83 4.16 5.35 6.31 11 34 174
Accounts Payable		 1.71 1.65 1.81 2.59 1.02 1.13 2.21 2.20 4.28 1.72 7.88
Accrued Expenses		 1.22 2.34 4.36 5.17 4.80 2.92 3.01 3.97 6.97 32 163
Other Current Liabilities		 - - - - 0.00 0.11 0.12 0.13 0.15 0.17 3.02
Total Noncurrent Liabilities		 0.03 0.00 0.00 6.13 0.00 0.92 0.80 0.67 0.52 0.35 247
Long-Term Debt		 - - 0.00 6.13 - - - - - 0.00 145
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - - 0.00
Other Noncurrent Operating Liabilities		 - - - 0.00 0.00 0.92 0.80 0.67 0.52 0.35 102
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 34 18 7.19 4.93 24 44 63 55 70 85 405
Total Preferred & Common Equity		 34 18 7.19 4.93 24 44 63 55 70 85 405
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 34 18 7.19 4.93 24 44 63 55 70 85 405
Common Stock		 128 137 159 184 219 262 308 330 392 424 582
Retained Earnings		 -94 -119 -152 -179 -195 -217 -246 -275 -322 -340 -177
Accumulated Other Comprehensive Income / (Loss)		 0.06 0.08 0.10 0.10 0.10 0.10 0.09 0.08 0.09 0.09 0.00

Quarterly Balance Sheets for CorMedix

This table presents CorMedix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 59 57 91 68 58 78 150 253 751 816 904
Total Current Assets		 57 55 89 63 53 73 145 248 260 383 481
Cash & Equivalents		 25 20 53 35 29 35 66 159 48 178 257
Short-Term Investments		 30 33 33 23 17 11 11 31 7.22 0.00 0.00
Accounts Receivable		 - - - - 0.21 17 55 43 159 155 161
Inventories, net		 - - - 2.32 4.01 6.65 7.49 9.63 29 31 39
Prepaid Expenses		 1.05 2.14 2.39 2.46 3.37 3.09 5.26 4.80 16 19 24
Plant, Property, & Equipment, net		 1.61 1.60 1.59 1.91 1.92 1.90 1.73 1.64 7.52 6.17 7.85
Total Noncurrent Assets		 0.84 0.81 0.78 2.71 2.62 2.53 2.99 2.90 484 426 416
Long-Term Investments		 0.10 0.10 0.10 0.10 0.10 0.11 0.11 0.11 23 24 27
Goodwill		 - - - - - - - - 18 30 30
Intangible Assets		 - - - 2.00 1.95 1.90 1.79 1.74 390 369 358
Noncurrent Deferred & Refundable Income Taxes		 - - - - - - - - 53 3.31 0.00
Total Liabilities & Shareholders' Equity		 59 57 91 68 58 78 150 253 751 816 904
Total Liabilities		 5.31 7.98 8.23 10 12 19 35 32 377 379 443
Total Current Liabilities		 4.67 7.39 7.67 9.53 11 18 34 32 134 129 187
Accounts Payable		 1.45 2.90 2.39 2.83 3.34 1.34 1.93 5.82 20 13 10
Accrued Expenses		 3.09 4.34 5.14 6.55 7.61 17 32 26 109 113 173
Other Current Liabilities		 0.14 0.14 0.15 0.15 0.16 0.16 0.17 0.18 3.25 3.18 3.91
Total Noncurrent Liabilities		 0.63 0.59 0.56 0.48 0.44 0.39 0.30 0.26 243 247 256
Long-Term Debt		 - - - - - - - - - - 145
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - 145 145 0.66
Other Noncurrent Operating Liabilities		 0.63 - - - 0.44 0.39 0.30 0.26 96 102 110
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 54 49 83 58 46 59 115 221 374 437 461
Total Preferred & Common Equity		 54 49 83 58 46 59 115 221 374 437 461
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 54 49 83 58 46 59 115 221 374 437 461
Common Stock		 340 346 390 394 396 412 434 520 565 575 573
Retained Earnings		 -286 -297 -307 -336 -350 -353 -319 -299 -191 -138 -112
Accumulated Other Comprehensive Income / (Loss)		 0.10 0.09 0.08 0.08 0.09 0.09 0.08 0.08 0.09 0.00 0.00

Annual Metrics And Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 54,812,042.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 54,812,042.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 2.97
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 11.02% 6.65% 46.95% 30.51% -34.09% -15.55% -20.19% -65.74% -100.00% 0.00% 585.12%
EBITDA Growth		 -1.91% -35.74% -34.03% 19.22% 22.95% -30.97% -8.31% -3.74% -60.58% 56.11% 867.57%
EBIT Growth		 -1.91% -35.77% -34.04% 19.09% 21.72% -29.33% -8.32% -3.83% -60.16% 55.36% 781.14%
NOPAT Growth		 -87.08% -48.68% -32.97% 18.41% 21.80% -29.57% -8.14% -4.03% -59.87% 54.34% 1,142.81%
Net Income Growth		 11.08% -35.50% -33.95% 18.72% 38.75% -34.04% -28.07% -5.29% -56.02% 61.31% 1,009.40%
EPS Growth		 39.58% -12.07% -33.95% 18.72% -19.21% 57.22% 0.00% 0.00% 0.00% 67.03% 780.00%
Operating Cash Flow Growth		 -98.18% -77.74% -28.39% 17.09% 36.49% -45.94% 3.70% -15.13% -57.70% -31.78% 445.84%
Free Cash Flow Firm Growth		 10.77% -51.21% -25.99% 17.35% 2.66% -30.29% 7.30% -1.79% -57.81% -69.72% -225.32%
Invested Capital Growth		 -119.25% -63.17% -96.72% -35.74% 27.80% 52.34% -25.21% -36.42% -53.29% 641.51% 1,036.87%
Revenue Q/Q Growth		 -12.07% 41.43% -8.14% -13.31% -0.61% 0.00% 0.00% -28.98% -100.00% 240.63% 41.37%
EBITDA Q/Q Growth		 -10.00% -12.26% -13.10% 31.67% -57.50% -2.01% -6.27% -2.16% -17.41% 57.74% 51.00%
EBIT Q/Q Growth		 -9.99% -12.27% -13.09% 31.60% -55.84% -2.38% -6.44% -2.16% -17.33% 57.12% 42.48%
NOPAT Q/Q Growth		 -11.21% -11.98% -12.77% 31.60% -55.69% -2.67% -6.11% -2.03% -17.47% 56.13% 3.40%
Net Income Q/Q Growth		 -9.99% -12.03% -13.00% 31.71% -82.99% -3.68% -6.43% -1.43% -16.45% 61.15% 0.34%
EPS Q/Q Growth		 -87.10% -14.04% -13.00% 31.71% -19.21% 0.00% 0.00% 0.00% 0.00% 0.00% -2.39%
Operating Cash Flow Q/Q Growth		 -19.69% -14.76% -2.80% 0.32% 18.05% -10.29% 0.30% -1.19% -13.57% 9.20% 133.49%
Free Cash Flow Firm Q/Q Growth		 -17.66% -16.30% 1.77% -22.69% 23.45% -9.60% -3.14% 5.51% -13.40% -6.47% -37.74%
Invested Capital Q/Q Growth		 5.25% 17.18% -98.16% 58.20% -24.64% 15.81% -5.16% -79.85% -101.22% 161.29% 24.83%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -51.68% -63.62% 65.09% 7.68% -31.76% 14.37% 22.00% 94.29% 0.00% 92.66% 92.58%
EBITDA Margin		 -8,675.05% -11,041.03% -10,070.21% -6,233.21% -7,287.37% -11,300.69% -15,335.95% -46,443.53% 0.00% -49.25% 55.18%
Operating Margin		 -7,925.56% -11,048.80% -9,997.39% -6,250.44% -7,416.31% -11,378.44% -15,417.51% -46,819.91% 0.00% -51.43% 50.41%
EBIT Margin		 -8,682.22% -11,052.45% -10,081.41% -6,250.48% -7,423.78% -11,368.54% -15,428.66% -46,763.12% 0.00% -50.30% 50.01%
Profit (Net Income) Margin		 -8,655.37% -10,996.46% -10,023.45% -6,242.40% -5,801.29% -9,207.70% -14,774.70% -45,409.90% 0.00% -41.24% 54.75%
Tax Burden Percent		 103.63% 100.00% 99.74% 100.00% 76.45% 80.99% 95.76% 98.07% 100.00% 92.78% 108.69%
Interest Burden Percent		 96.20% 99.49% 99.68% 99.87% 102.21% 100.00% 100.01% 99.02% 94.60% 88.37% 100.71%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.69%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -116.81% 80.29%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -113.25% 80.62%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.64% -13.74%
Return on Equity (ROE)		 -96.62% -95.10% -264.00% -442.46% -114.99% -64.91% -52.72% -50.40% -74.02% -23.17% 66.56%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -166.09% -87.37%
Operating Return on Assets (OROA)		 -86.47% -83.95% -187.79% -166.45% -87.07% -69.04% -49.82% -46.70% 0.00% -21.77% 31.52%
Return on Assets (ROA)		 -86.20% -83.53% -186.71% -166.23% -68.04% -55.92% -47.71% -45.35% 0.00% -17.85% 34.51%
Return on Common Equity (ROCE)		 -96.62% -95.10% -263.99% -442.42% -114.99% -64.91% -52.72% -50.40% -74.02% -23.17% 66.56%
Return on Equity Simple (ROE_SIMPLE)		 -53.47% -138.33% -458.89% -543.74% -69.50% -49.81% -44.92% -53.94% -66.06% -21.18% 0.00%
Net Operating Profit after Tax (NOPAT)		 -12 -17 -23 -19 -15 -19 -21 -21 -34 -16 163
NOPAT Margin		 -5,547.89% -7,734.16% -6,998.17% -4,375.31% -5,191.41% -7,964.91% -10,792.26% -32,773.94% 0.00% -36.00% 54.79%
Net Nonoperating Expense Percent (NNEP)		 -32.73% -26.16% -61.33% -67.36% -8.60% -7.92% -13.55% -13.25% -17.85% -3.56% -0.33%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -48.86% -18.49% 29.67%
Cost of Revenue to Revenue		 -151.68% 163.62% 34.91% 92.32% 131.76% 85.63% 78.00% 5.71% 0.00% 7.34% 7.42%
SG&A Expenses to Revenue		 4,884.39% 3,963.79% 2,627.28% 1,878.73% 3,482.59% 5,801.06% 8,561.30% 30,586.61% 0.00% 68.92% 22.91%
R&D to Revenue		 2,989.49% 7,021.40% 7,435.20% 4,379.39% 3,901.95% 5,591.75% 6,878.21% 16,327.59% 0.00% 9.07% 6.49%
Operating Expenses to Revenue		 7,873.88% 10,985.19% 10,062.48% 6,258.12% 7,384.55% 11,392.81% 15,439.51% 46,914.20% 0.00% 144.09% 42.17%
Earnings before Interest and Taxes (EBIT)		 -18 -25 -33 -27 -21 -27 -29 -31 -49 -22 149
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -25 -33 -27 -21 -27 -29 -30 -49 -21 164
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.87 3.26 19.24 23.29 7.44 4.80 2.73 3.41 2.73 5.63 2.30
Price to Tangible Book Value (P/TBV)		 1.87 3.26 19.24 23.29 7.44 4.80 2.73 3.41 2.73 5.76 0.00
Price to Revenue (P/Rev)		 302.80 259.21 420.26 267.38 620.71 887.07 897.58 2,871.04 0.00 10.97 3.14
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.73
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17.46%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.93 2.42
Enterprise Value to Revenue (EV/Rev)		 133.59 168.46 383.36 240.22 520.07 692.53 553.49 1,968.73 0.00 9.78 3.03
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.49
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.06
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.53
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.15
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 1.24 0.00 0.00 0.00 0.00 0.00 0.00 0.36
Long-Term Debt to Equity		 0.00 0.00 0.00 1.24 0.00 0.00 0.00 0.00 0.00 0.00 0.36
Financial Leverage		 -1.06 -1.08 -1.30 -1.96 -1.41 -1.11 -1.05 -1.06 -1.08 -0.83 -0.17
Leverage Ratio		 1.12 1.14 1.41 2.66 1.69 1.16 1.11 1.11 1.15 1.30 1.93
Compound Leverage Factor		 1.08 1.13 1.41 2.66 1.73 1.16 1.11 1.10 1.09 1.15 1.94
Debt to Total Capital		 0.00% 0.00% 0.00% 55.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.30%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 55.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.30%
Preferred Equity to Total Capital		 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 99.99% 44.61% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 73.70%
Debt to EBITDA		 0.00 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.88
Net Debt to EBITDA		 0.00 0.00 0.00 0.44 0.00 0.00 0.00 0.00 0.00 0.00 -0.19
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.88
Debt to NOPAT		 0.00 0.00 0.00 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.89
Net Debt to NOPAT		 0.00 0.00 0.00 0.62 0.00 0.00 0.00 0.00 0.00 0.00 -0.19
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.89
Altman Z-Score		 8.27 -1.85 -10.06 -12.34 7.43 18.12 11.40 9.34 3.17 4.94 2.27
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.11 5.34 2.12 2.40 5.04 11.58 12.44 9.44 6.97 3.39 2.11
Quick Ratio		 11.66 4.93 1.92 2.27 4.86 11.14 12.26 9.32 6.67 3.05 1.83
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -16 -21 -17 -17 -22 -20 -20 -32 -55 -178
Operating Cash Flow to CapEx		 -81,101.24% -37,915.97% -18,808.84% -48,474.35% -41,158.36% -19,502.87% -1,484.23% -11,103.54% -11,735.25% -43,735.12% 7,745.40%
Free Cash Flow to Firm to Interest Expense		 -2,728.80 -12,476.03 -3,667.41 -9,093.13 -21.05 -650.09 -1,255.85 -768.62 -937.74 -1,499.31 -63.83
Operating Cash Flow to Interest Expense		 -3,160.17 -16,983.52 -5,087.59 -12,653.80 -19.11 -661.16 -1,326.93 -918.60 -1,119.94 -1,390.32 62.92
Operating Cash Flow Less CapEx to Interest Expense		 -3,164.06 -17,028.31 -5,114.64 -12,679.90 -19.16 -664.55 -1,416.33 -926.88 -1,129.48 -1,393.50 62.11
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.02 0.03 0.01 0.01 0.00 0.00 0.00 0.43 0.63
Accounts Receivable Turnover		 1.06 1.37 8.65 11.45 51.79 141.06 7.84 0.00 0.00 0.00 2.67
Inventory Turnover		 0.00 1.35 0.30 0.78 0.97 0.85 2.03 0.00 0.00 0.66 1.18
Fixed Asset Turnover		 5.30 4.17 2.57 2.48 2.00 2.05 0.24 0.04 0.00 23.54 76.49
Accounts Payable Turnover		 0.00 0.22 0.07 0.18 0.21 0.19 0.09 0.00 0.00 1.06 4.60
Days Sales Outstanding (DSO)		 343.89 266.93 42.21 31.87 7.05 2.59 46.57 0.00 0.00 0.00 136.57
Days Inventory Outstanding (DIO)		 0.00 270.41 1,207.94 470.39 375.03 429.45 179.60 0.00 0.00 555.18 308.31
Days Payable Outstanding (DPO)		 0.00 1,669.69 5,482.44 2,022.51 1,766.77 1,917.59 4,089.77 215,622.77 0.00 343.19 79.35
Cash Conversion Cycle (CCC)		 343.89 -1,132.35 -4,232.30 -1,520.25 -1,384.69 -1,485.55 -3,863.60 -215,622.77 0.00 211.99 365.53
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.55 -2.52 -4.96 -6.74 -4.86 -2.32 -2.90 -3.96 -6.07 33 374
Invested Capital Turnover		 -0.19 -0.11 -0.09 -0.07 -0.05 -0.07 -0.07 -0.02 0.00 3.24 1.47
Increase / (Decrease) in Invested Capital		 -0.84 -0.98 -2.44 -1.77 1.87 2.55 -0.58 -1.06 -2.11 39 341
Enterprise Value (EV)		 28 38 126 103 147 166 106 129 115 425 902
Market Capitalization		 64 58 138 115 176 212 171 188 191 477 934
Book Value per Share		 $0.96 $0.44 $0.11 $0.05 $0.92 $1.38 $1.65 $1.33 $1.28 $1.44 $5.63
Tangible Book Value per Share		 $0.96 $0.44 $0.11 $0.05 $0.92 $1.38 $1.65 $1.33 $1.28 $1.41 ($0.05)
Total Capital		 34 18 7.19 11 24 44 63 55 70 85 550
Total Debt		 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00 0.00 0.00 145
Total Long-Term Debt		 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00 0.00 0.00 145
Net Debt		 -36 -20 -12 -12 -29 -47 -66 -59 -76 -52 -32
Capital Expenditures (CapEx)		 0.02 0.06 0.15 0.05 0.04 0.11 1.43 0.22 0.33 0.12 2.26
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.56 -2.60 -5.15 -6.90 -4.99 -2.52 -4.47 -5.68 -8.06 29 44
Debt-free Net Working Capital (DFNWC)		 34 18 7.01 11 24 44 61 53 68 81 193
Net Working Capital (NWC)		 34 18 7.01 11 24 44 61 53 68 81 193
Net Nonoperating Expense (NNE)		 6.53 7.31 9.96 8.02 1.73 2.97 7.60 8.26 12 2.28 0.14
Net Nonoperating Obligations (NNO)		 -36 -20 -12 -12 -29 -47 -66 -59 -76 -52 -32
Total Depreciation and Amortization (D&A)		 0.02 0.03 0.04 0.07 0.39 0.16 0.18 0.21 0.21 0.46 15
Debt-free, Cash-free Net Working Capital to Revenue		 -742.33% -1,158.89% -1,563.31% -1,604.59% -1,760.62% -1,053.49% -2,343.31% -8,678.15% 0.00% 66.82% 14.86%
Debt-free Net Working Capital to Revenue		 16,179.27% 7,915.86% 2,127.69% 2,535.81% 8,303.90% 18,400.87% 32,012.69% 81,397.21% 0.00% 185.72% 64.73%
Net Working Capital to Revenue		 16,179.27% 7,915.86% 2,127.69% 2,535.81% 8,303.90% 18,400.87% 32,012.69% 81,397.21% 0.00% 185.72% 64.73%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) ($0.74) ($0.91) ($0.30) $2.25
Adjusted Weighted Average Basic Shares Outstanding		 7.22M 8.14M 16.30M 119.01M 26.13M 38.02M 38.73M 40.27M 50.90M 58.87M 72.03M
Adjusted Diluted Earnings per Share		 ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) $0.00 $0.00 ($0.30) $2.04
Adjusted Weighted Average Diluted Shares Outstanding		 7.22M 8.14M 16.30M 119.01M 26.13M 38.02M 38.73M 44.50M 54.98M 58.87M 80.31M
Adjusted Basic & Diluted Earnings per Share		 ($2.90) ($3.25) ($3.00) ($0.30) ($1.80) ($0.77) ($0.75) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.27M 7.59M 11.03M 89.08M 24.15M 28.56M 37.67M 44.50M 54.98M 0.00 79.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -17 -23 -19 -15 -19 -21 -21 -34 -16 105
Normalized NOPAT Margin		 -5,547.89% -7,734.16% -6,998.17% -4,375.31% -5,191.41% -7,964.91% -10,792.26% -32,773.94% 0.00% -36.00% 35.29%
Pre Tax Income Margin		 -8,352.02% -10,996.46% -10,049.50% -6,242.40% -7,587.87% -11,368.54% -15,429.47% -46,305.23% 0.00% -44.45% 50.37%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4,602.41 -18,893.28 -5,908.67 -14,342.97 -26.70 -818.55 -1,847.76 -1,153.57 -1,428.35 -600.66 53.54
NOPAT to Interest Expense		 -2,940.91 -13,220.93 -4,101.60 -10,040.01 -18.67 -573.48 -1,292.50 -808.48 -999.26 -429.87 58.66
EBIT Less CapEx to Interest Expense		 -4,606.31 -18,938.07 -5,935.72 -14,369.07 -26.75 -821.94 -1,937.16 -1,161.84 -1,437.90 -603.84 52.73
NOPAT Less CapEx to Interest Expense		 -2,944.81 -13,265.73 -4,128.65 -10,066.11 -18.72 -576.87 -1,381.90 -816.75 -1,008.80 -433.05 57.85
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -1.38% 0.00% 0.00% 0.00% 0.00% 0.00% 3.51%

Quarterly Metrics And Ratios for CorMedix

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 54,812,042.00 54,812,042.00 78,451,891.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 54,812,042.00 54,812,042.00 78,451,891.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - 0.26 0.70 0.33
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,829.40% 778.54% 279.28% 226.05% 156.52%
EBITDA Growth		 -86.34% -51.99% -29.08% 69.31% 187.33% 221.84% 234.32% 1,836.63% 422.57% 218.12% 127.79%
EBIT Growth		 -85.77% -51.83% -29.48% 68.36% 185.94% 220.22% 231.92% 1,664.87% 342.59% 169.55% 77.82%
NOPAT Growth		 -86.77% -51.62% -29.62% 68.59% 217.94% 272.11% 277.79% 4,707.41% 13.52% 119.43% 51.19%
Net Income Growth		 -79.73% -36.90% -25.53% 71.50% 191.26% 242.71% 240.11% 4,009.63% 4.13% 86.98% 31.07%
EPS Growth		 0.00% 0.00% 0.00% 70.59% 0.00% 220.00% 212.00% 2,620.00% -20.00% 43.33% 3.57%
Operating Cash Flow Growth		 -74.59% -66.54% -63.78% -56.94% 47.75% 214.02% 313.62% 326.06% 1,782.34% 114.73% 187.54%
Free Cash Flow Firm Growth		 -83.95% -72.13% -83.70% -174.78% -193.47% -30.28% 27.07% -909.86% -1,154.30% -795.46% -2,458.05%
Invested Capital Growth		 -53.29% 87.29% 115.93% 517.02% 641.51% 15,531.26% 6,253.91% 2,279.74% 1,036.87% 536.32% 980.45%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 777.11% 168.07% 27.26% 1.68% 153.28% 17.61% 7.65% -20.01%
EBITDA Q/Q Growth		 -49.49% -6.64% 8.78% 78.89% 525.33% 48.78% -2.75% 182.19% 23.29% -3.58% -29.40%
EBIT Q/Q Growth		 -49.26% -6.64% 8.41% 78.30% 505.46% 49.19% -2.79% 166.11% 10.41% -3.01% -34.97%
NOPAT Q/Q Growth		 -49.69% -6.61% 8.40% 78.52% 662.16% 55.58% -5.38% 456.76% -86.15% 200.70% -34.80%
Net Income Q/Q Growth		 -51.41% 1.95% 2.18% 80.38% 584.89% 53.32% -3.95% 447.52% -87.09% 175.33% -32.68%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.67% 350.00% -84.13% 115.00% -32.56%
Operating Cash Flow Q/Q Growth		 -23.55% -61.09% 18.89% 2.78% 58.87% 451.53% 51.96% 2.88% 206.13% -55.13% 103.48%
Free Cash Flow Firm Q/Q Growth		 -36.02% -50.74% -5.78% -26.69% -45.28% 33.08% 40.78% -1,654.24% -80.44% 52.22% -69.16%
Invested Capital Q/Q Growth		 -101.22% 96.02% 294.22% 2,580.55% 161.29% 13.44% -20.03% 903.95% 24.83% -36.51% 35.79%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 22.68% 94.01% 97.80% 95.91% 95.31% 92.48% 90.65% 82.50% 75.66%
EBITDA Margin		 0.00% 0.00% -1,162.91% -27.98% 44.40% 51.91% 49.65% 55.32% 57.99% 51.94% 45.84%
Operating Margin		 0.00% 0.00% -1,171.47% -28.70% 42.12% 51.50% 49.18% 51.02% 49.95% 49.96% 42.10%
EBIT Margin		 0.00% 0.00% -1,171.59% -28.99% 43.84% 51.40% 49.14% 51.63% 48.47% 43.67% 35.50%
Profit (Net Income) Margin		 0.00% 0.00% -1,083.48% -24.24% 43.84% 52.82% 49.90% 107.87% 11.84% 30.29% 25.50%
Tax Burden Percent		 100.00% 91.21% 100.00% 100.00% 100.00% 100.00% 97.44% 206.49% 24.84% 69.37% 67.10%
Interest Burden Percent		 94.17% 94.93% 92.48% 83.62% 100.00% 102.77% 104.21% 101.18% 98.38% 100.00% 107.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.56% -106.49% 75.16% 30.63% 32.90%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -53.62% 136.68% 229.55% 384.50% 142.31% 18.18% 97.51% 71.97%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -52.90% 135.86% 228.79% 383.83% 138.11% 19.78% 101.52% 73.67%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 49.34% -112.34% -179.78% -340.27% -38.59% -3.37% -51.03% -35.63%
Return on Equity (ROE)		 -74.02% -89.76% -111.55% -4.28% 24.34% 49.77% 44.23% 103.72% 14.81% 46.48% 36.35%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -9,401.45% -407.60% -166.09% -61.83% 128.63% -82.67% -87.37% -7.62% -52.61%
Operating Return on Assets (OROA)		 0.00% 0.00% -26.67% -4.38% 18.97% 39.00% 38.47% 26.26% 30.55% 34.94% 27.52%
Return on Assets (ROA)		 0.00% 0.00% -24.66% -3.66% 18.97% 40.08% 39.07% 54.86% 7.47% 24.24% 19.77%
Return on Common Equity (ROCE)		 -74.02% -89.76% -111.55% -4.28% 24.34% 49.77% 44.23% 103.72% 14.81% 46.48% 36.35%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -86.60% -115.01% -78.60% 0.00% 14.95% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -12 -11 -2.30 13 20 19 106 15 44 29
NOPAT Margin		 0.00% 0.00% -820.03% -20.09% 42.12% 51.50% 47.92% 105.34% 12.41% 34.65% 28.25%
Net Nonoperating Expense Percent (NNEP)		 -5.60% -4.86% -7.04% -0.72% 0.83% 0.76% 0.66% 4.20% -1.59% -4.01% -1.70%
Return On Investment Capital (ROIC_SIMPLE)		 -15.64% - - - 15.28% 17.52% 8.63% 28.05% 2.67% 10.10% 4.75%
Cost of Revenue to Revenue		 0.00% 0.00% 39.03% 5.99% 3.83% 4.09% 4.69% 7.52% 9.35% 17.50% 24.34%
SG&A Expenses to Revenue		 0.00% 0.00% 578.76% 57.44% 2.51% 24.80% 23.92% 25.29% 19.91% 17.05% 14.80%
R&D to Revenue		 0.00% 0.00% 49.84% 6.35% 5.62% 8.17% 6.15% 5.06% 7.27% 5.66% 6.56%
Operating Expenses to Revenue		 0.00% 0.00% 1,194.16% 122.70% 55.68% 44.42% 46.13% 41.47% 40.70% 32.54% 33.57%
Earnings before Interest and Taxes (EBIT)		 -16 -17 -15 -3.32 13 20 20 52 57 56 36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -17 -15 -3.21 14 20 20 56 69 66 47
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.73 4.02 5.24 8.10 5.63 3.70 4.02 2.68 2.30 1.44 1.58
Price to Tangible Book Value (P/TBV)		 2.73 4.16 5.47 8.37 5.76 3.76 4.05 0.00 0.00 16.50 10.03
Price to Revenue (P/Rev)		 0.00 0.00 185.19 37.24 10.97 5.15 7.29 4.76 3.14 1.63 1.62
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 24.73 17.32 6.17 5.73 3.49 3.88
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 4.04% 5.77% 16.21% 17.46% 28.67% 25.78%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 418.06 34.12 12.93 9.32 23.32 3.10 2.42 1.81 1.82
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 150.18 33.63 9.78 4.21 5.72 4.40 3.03 1.11 1.31
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 22.36 13.92 8.53 5.49 2.20 2.65
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 23.26 14.11 8.88 6.06 2.33 2.94
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 23.99 14.24 5.88 5.53 2.26 2.94
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 22.82 12.38 5.15 2.17 2.31
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 35.70 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.36 0.00 0.32
Long-Term Debt to Equity		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.36 0.00 0.32
Financial Leverage		 -1.08 -1.02 -1.03 -0.93 -0.83 -0.79 -0.89 -0.28 -0.17 -0.50 -0.48
Leverage Ratio		 1.15 1.14 1.21 1.19 1.30 1.26 1.16 1.91 1.93 1.75 1.70
Compound Leverage Factor		 1.08 1.08 1.11 1.00 1.30 1.29 1.21 1.94 1.90 1.75 1.82
Debt to Total Capital		 0.00% 0.81% 0.00% 0.00% 0.00% 0.00% 0.00% 1.01% 26.30% 0.00% 23.95%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.22% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.79% 26.30% 0.00% 23.95%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 99.18% 100.00% 100.00% 100.00% 100.00% 100.00% 98.99% 73.70% 100.00% 76.05%
Debt to EBITDA		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.04 0.88 0.00 0.66
Net Debt to EBITDA		 0.00 1.07 0.00 0.00 0.00 0.00 0.00 -0.69 -0.19 0.00 -0.63
Long-Term Debt to EBITDA		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.03 0.88 0.00 0.66
Debt to NOPAT		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.89 0.00 0.73
Net Debt to NOPAT		 0.00 1.52 0.00 0.00 0.00 0.00 0.00 -0.47 -0.19 0.00 -0.69
Long-Term Debt to NOPAT		 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.89 0.00 0.73
Altman Z-Score		 4.51 7.19 4.10 9.61 5.92 6.24 16.74 1.95 1.90 1.84 1.83
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.97 6.65 4.79 3.96 3.39 4.21 7.82 1.94 2.11 2.98 2.56
Quick Ratio		 6.67 6.14 4.12 3.43 3.05 3.84 7.37 1.60 1.83 2.59 2.23
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.86 -13 -14 -18 -26 -17 -10 -181 -326 -156 -264
Operating Cash Flow to CapEx		 -3,631.15% -28,235.89% -40,357.34% -139,769.68% -56,890.63% 193,932.43% 125,252.93% 6,100.85% 5,491.60% 5,813.72% 15,372.01%
Free Cash Flow to Firm to Interest Expense		 -1,351.17 -1,357.69 -2,154.45 -1,788.21 -2,597.87 -1,738.42 -1,544.21 -190.58 -179.45 0.00 0.00
Operating Cash Flow to Interest Expense		 -1,639.06 -1,760.07 -2,141.54 -1,364.04 -561.06 1,972.27 4,495.85 32.54 51.99 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -1,684.20 -1,766.30 -2,146.84 -1,365.01 -562.05 1,971.25 4,492.26 32.01 51.04 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.02 0.15 0.43 0.76 0.78 0.51 0.63 0.80 0.78
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 5.64 2.39 2.67 3.69 4.39
Inventory Turnover		 0.00 0.00 0.00 0.00 0.66 0.81 0.78 0.69 1.18 2.24 2.73
Fixed Asset Turnover		 0.00 0.00 0.74 7.32 23.54 45.44 68.31 44.73 76.49 97.84 94.46
Accounts Payable Turnover		 0.00 0.38 0.43 1.08 1.06 1.67 1.16 1.12 4.60 5.80 8.19
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 64.77 152.43 136.57 98.97 83.12
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 555.18 451.02 468.00 529.74 308.31 162.98 133.86
Days Payable Outstanding (DPO)		 0.00 952.68 858.02 337.83 343.19 218.86 314.16 324.68 79.35 62.94 44.57
Cash Conversion Cycle (CCC)		 0.00 0.00 -858.02 -337.83 211.99 232.16 218.62 357.50 365.53 199.00 172.41
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -6.07 -0.24 0.47 13 33 37 30 299 374 237 322
Invested Capital Turnover		 0.00 0.00 -1.06 2.67 3.24 4.46 8.02 1.35 1.47 2.81 2.55
Increase / (Decrease) in Invested Capital		 -2.11 1.66 3.41 16 39 38 29 287 341 200 292
Enterprise Value (EV)		 115 175 196 429 425 347 695 928 902 429 587
Market Capitalization		 191 233 242 475 477 425 886 1,003 934 631 726
Book Value per Share		 $1.28 $1.01 $0.80 $1.00 $1.44 $1.76 $3.25 $4.93 $5.63 $5.50 $5.87
Tangible Book Value per Share		 $1.28 $0.97 $0.77 $0.97 $1.41 $1.73 $3.22 ($0.44) ($0.05) $0.48 $0.92
Total Capital		 70 58 46 59 85 115 221 378 550 437 606
Total Debt		 0.00 0.48 0.00 0.00 0.00 0.00 0.00 3.81 145 0.00 145
Total Long-Term Debt		 0.00 0.48 0.00 0.00 0.00 0.00 0.00 2.97 145 0.00 145
Net Debt		 -76 -58 -46 -46 -52 -78 -191 -75 -32 -202 -139
Capital Expenditures (CapEx)		 0.30 0.06 0.03 0.01 0.01 0.01 0.02 0.51 1.72 0.73 0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.06 -4.75 -3.53 8.64 29 33 26 71 44 76 36
Debt-free Net Working Capital (DFNWC)		 68 54 42 55 81 110 216 127 193 254 293
Net Working Capital (NWC)		 68 54 42 55 81 110 216 126 193 254 293
Net Nonoperating Expense (NNE)		 3.79 2.77 3.44 0.48 -0.53 -0.52 -0.79 -2.54 0.67 5.56 2.80
Net Nonoperating Obligations (NNO)		 -76 -58 -46 -46 -52 -78 -191 -75 -32 -200 -139
Total Depreciation and Amortization (D&A)		 0.05 0.06 0.11 0.11 0.17 0.20 0.20 3.71 11 11 11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -270.06% 67.73% 66.82% 39.94% 21.10% 33.71% 14.86% 19.74% 8.13%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 3,221.99% 428.40% 185.72% 133.82% 178.09% 60.16% 64.73% 65.86% 65.38%
Net Working Capital to Revenue		 0.00% 0.00% 3,221.99% 428.40% 185.72% 133.82% 178.09% 59.76% 64.73% 65.86% 65.38%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.25) ($0.25) ($0.25) ($0.05) $0.25 $0.32 $0.29 $1.42 $0.22 $0.48 $0.33
Adjusted Weighted Average Basic Shares Outstanding		 50.90M 57.50M 57.62M 58.83M 58.87M 65.24M 67.93M 75.93M 72.03M 79.51M 78.44M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.05) $0.00 $0.30 $0.28 $1.26 $0.20 $0.43 $0.29
Adjusted Weighted Average Diluted Shares Outstanding		 50.90M 54.96M 55.86M 58.83M 58.87M 68.98M 71.92M 86.21M 80.31M 92.99M 92.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.98M 54.96M 55.86M 60.68M 0.00 67.82M 74.65M 78.79M 79.05M 78.45M 77.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -12 -11 -2.30 9.06 14 19 36 41 44 29
Normalized NOPAT Margin		 0.00% 0.00% -820.03% -20.09% 29.49% 36.05% 47.92% 35.71% 34.96% 34.65% 28.25%
Pre Tax Income Margin		 0.00% 0.00% -1,083.48% -24.24% 43.84% 52.82% 51.21% 52.24% 47.69% 43.67% 38.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2,389.80 -1,698.86 -2,334.09 -331.83 1,345.46 2,007.31 2,927.18 54.80 31.57 0.00 0.00
NOPAT to Interest Expense		 -1,672.99 -1,188.91 -1,633.71 -229.95 1,292.70 2,011.12 2,854.54 111.81 8.08 0.00 0.00
EBIT Less CapEx to Interest Expense		 -2,434.94 -1,705.09 -2,339.40 -332.81 1,344.47 2,006.29 2,923.59 54.27 30.63 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -1,718.13 -1,195.15 -1,639.01 -230.93 1,291.71 2,010.10 2,850.95 111.28 7.14 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.51% 9.29% 12.40%

Financials Breakdown Chart

Key Financial Trends

CorMedix’s financial profile has improved substantially over the past several years, driven by the commercial ramp of its product revenue. Revenue increased from less than $1 million in the second quarter of 2024 to $101.9 million in Q2 2026. The company has also moved from sizable operating and net losses to profitability, although Q2 results were weaker than Q1 on a sequential basis.

Q2 2026 revenue declined 20.1% from $127.4 million in Q1, but was approximately 157% higher than the restated $39.7 million reported in Q2 2025. Gross profit was $77.1 million, representing a strong 75.7% gross margin. Net income totaled $26.0 million, down from $38.6 million in Q1 but well above the $19.8 million recorded in the year-ago quarter.

Cash generation was particularly strong in the latest quarter. Operating cash flow more than doubled sequentially to $86.2 million, helping cash and equivalents rise to $256.7 million from $178.1 million at the end of Q1. However, CorMedix also carries $145.2 million of long-term debt, and its balance sheet has become more dependent on accrued and other noncurrent liabilities following the company’s rapid expansion.

  • Revenue growth remains the dominant positive trend: Quarterly revenue rose from $30.7 million in Q4 2024 to $118.4 million in Q4 2025 and $101.9 million in Q2 2026, compared with only $806,000 in Q2 2024.
  • CorMedix has achieved sustained profitability: The company reported net income in Q1 and Q2 2026, as well as Q2 and Q4 2025, reversing losses of $8 million to $15 million in comparable 2022–2024 quarters.
  • Gross margins are strong: Q2 2026 gross profit was $77.1 million on $101.9 million of revenue, or approximately 75.7%. Gross margin was also about 82.3% in Q1 2026 and 90.8% in Q4 2025.
  • Operating cash flow has turned meaningfully positive: Operating cash flow increased from negative $13.6 million in Q3 2024 to $94.5 million in Q4 2025, $42.4 million in Q1 2026 and $86.2 million in Q2 2026.
  • Liquidity has expanded sharply: Cash and equivalents increased to $256.7 million in Q2 2026 from $28.5 million in Q2 2024. Total current assets of $480.6 million exceeded current liabilities of $187.4 million by a wide margin.
  • Retained earnings are improving: The accumulated deficit narrowed to $112.0 million in Q2 2026 from $299.2 million in Q2 2025 and $353.1 million in Q3 2024, reflecting the company’s recent earnings growth.
  • Q2 performance softened sequentially: Revenue, gross profit, operating income and diluted EPS all declined from Q1 2026. Diluted EPS fell to $0.29 from $0.43, although the latest quarter remained profitable.
  • Working-capital movements boosted recent cash flow: Changes in operating assets and liabilities contributed $47.2 million to Q2 2026 operating cash flow. Investors should monitor whether this benefit is recurring, particularly as accounts receivable reached $161.3 million.
  • Debt and liabilities have increased: Long-term debt was $145.2 million in Q2 2026, compared with no reported long-term debt in Q1. Total liabilities rose to $443.2 million from $378.6 million in Q1.
  • The balance sheet contains significant intangible assets: Intangible assets totaled $358.5 million, or nearly 40% of total assets, while goodwill added another $30.0 million. Any impairment or decline in the value of acquired assets could pressure equity and earnings.

Overall, the statements show a company transitioning from a development-stage cash burner into a profitable, cash-generating commercial business. The strongest evidence is the combination of rapid revenue growth, high gross margins, positive net income and substantial operating cash flow. The main risks are the sequential revenue slowdown, rising liabilities, reliance on working-capital inflows and the large intangible-asset balance.

09/18/26 04:54 PM ETAI Generated. May Contain Errors.

CorMedix Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CorMedix's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

CorMedix's net income appears to be on a downward trend, with a most recent value of $163.06 million in 2025, falling from -$18.19 million in 2015. The previous period was -$17.93 million in 2024. View CorMedix's forecast to see where analysts expect CorMedix to go next.

CorMedix's total operating income in 2025 was $150.14 million, based on the following breakdown:
  • Total Gross Profit: $275.75 million
  • Total Operating Expenses: $125.61 million

Over the last 10 years, CorMedix's total revenue changed from $210.13 thousand in 2015 to $297.84 million in 2025, a change of 141,639.4%.

CorMedix's total liabilities were at $420.84 million at the end of 2025, a 1,130.9% increase from 2024, and a 13,518.2% increase since 2015.

In the past 10 years, CorMedix's cash and equivalents has ranged from $8.06 million in 2016 to $144.84 million in 2025, and is currently $144.84 million as of their latest financial filing in 2025.

Over the last 10 years, CorMedix's book value per share changed from 0.96 in 2015 to 5.63 in 2025, a change of 485.3%.


Related Companies

Financial statements for NASDAQ:CRMD last updated on 8/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel
Iran War: What Happened at 1:11 P.M. Outside D.C.?
A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...
Banyan Hill Publishing | Sponsoredtc pixel
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...
Stansberry Research | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
SPDR Gold just lost $14 billion.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel